Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
9
×
Tags
cancer
9
×
life sciences
9
×
national blog main
biotech
boston blog main
boston top stories
san diego blog main
san diego top stories
san francisco blog main
detroit blog main
detroit top stories
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
eli lilly
indiana blog main
indiana top stories
national
cancer immunotherapy
fda
startups
deals
merck
pfizer
abbvie
alzheimer's disease
boehringer ingelheim
bristol-myers squibb
What
companies
9
×
bio
roundup
drug
life
ipo
new
science
therapeutics
week
approved
biotechs
black
cancer
diamond
latest
leading
merck
nash
news
pharmaceutical
price
sciences
admits
ago
alzheimer’s
approval
arena’s
big
biogen’s
biopharmaceutical
biotech
bounty
cig
classes
clinic
club
combinator
combo
comeback
Language
unset
Current search:
companies
×
cancer
×
" life sciences "
×
photo
×
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M